Publication:
Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS >= 50%: KEYNOTE-598

Simple item page
dc.contributor.authorsBoyer, M.; Sendur, M. A. N.; Rodriguez-Abreu, D.; Park, K.; Lee, D. H.; Cicin, I.; Yumuk, P. F.; Orlandi, F.; Leal, T.; Molinier, O.; Soparattanapaisam, N.; Langleben, A.; Califano, R.; Medgyasszay, B.; Hsia, T.; Otterson, G.; Xu, L.; Piperdi, B.; Samkari, A.; Reck, M.
dc.date.accessioned2022-03-10T18:03:15Z
dc.date.accessioned2026-01-11T17:35:31Z
dc.date.available2022-03-10T18:03:15Z
dc.date.issued2021
dc.identifier.doidoiWOS:000631349600006
dc.identifier.eissn1556-1380
dc.identifier.issn1556-0864
dc.identifier.urihttps://hdl.handle.net/11424/222461
dc.identifier.wosWOS:000631349600006
dc.language.isoeng
dc.publisherELSEVIER SCIENCE INC
dc.relation.ispartofJOURNAL OF THORACIC ONCOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectPhase III trial
dc.subjectRelapsed Malignant Mesothelioma
dc.subjectImmune-checkpoint-inhibitor
dc.titlePembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS >= 50%: KEYNOTE-598
dc.typeconferenceObject
dc.type.submeetingabstract
dspace.entity.typePublication
oaire.citation.endPageS62
oaire.citation.issue3
oaire.citation.startPageS61
oaire.citation.titleJOURNAL OF THORACIC ONCOLOGY
oaire.citation.volume16

Files

Collections

Araştırma Çıktıları